Notice of 9th AGM and Annual Report FY2025-26

Board & Shareholder Meetings View source PDF Explain this filing

SOLARA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.5%1-day move

₹626.90

prior close

₹630.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.8+0.4-0.3-0.1-2.5-0.5+0.8+2.5+1.6+1.6+18.0———

Up moveDown movePending

AI summary

Solara Active Pharma Sciences filed the Notice of its 9th AGM on September 18, 2026 at 10:30 AM via Video Conference, along with the Annual Report for FY2025-26. Revenue rose 7 percent to Rs 1,375 crore, driven by 6 percent growth in the base API business (Rs 1,041 crore) with EBITDA of Rs 245 crore. Overall EBITDA was Rs 192 crore. The Ibuprofen business posted an EBITDA loss of Rs 53 crore. Net loss was Rs 7 crore. Net debt fell to Rs 614 crore from Rs 772 crore.

Likely market impact

AGM on Sept 18, 2026. E-voting Sept 15-17. Mixed FY25-26 results with base API business growing while Ibuprofen segment continued to drag overall profitability.